Dumont Blake Investment Advisors Lowers stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Dumont Blake Investment Advisors reduced its stake in Abbott Laboratories by 1.41% during the most recent quarter end. The investment management company now holds a total of 19,275 shares of Abbott Laboratories which is valued at $849,642 after selling 275 shares in Abbott Laboratories , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Abbott Laboratories makes up approximately 0.44% of Dumont Blake Investment Advisors’s portfolio.

Abbott Laboratories closed down -0.05 points or -0.11% at $43.83 with 50,35,092 shares getting traded on Wednesday. Post opening the session at $43.93, the shares hit an intraday low of $43.69 and an intraday high of $44 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Advisory Services Network reduced its stake in ABT by selling 3,987 shares or 64.08% in the most recent quarter. The Hedge Fund company now holds 2,235 shares of ABT which is valued at $98,519. Abbott Laboratories makes up approx 0.03% of Advisory Services Network’s portfolio.Woodley Farra Manion Portfolio Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 7,375 shares of Abbott Laboratories which is valued at $325,090. Abbott Laboratories makes up approx 0.05% of Woodley Farra Manion Portfolio Management Inc’s portfolio.Bennicas Associates reduced its stake in ABT by selling 1,000 shares or 4.77% in the most recent quarter. The Hedge Fund company now holds 19,974 shares of ABT which is valued at $880,454. Abbott Laboratories makes up approx 0.82% of Bennicas Associates’s portfolio.Rnc Capital Management reduced its stake in ABT by selling 243 shares or 2.62% in the most recent quarter. The Hedge Fund company now holds 9,045 shares of ABT which is valued at $392,643. Abbott Laboratories makes up approx 0.04% of Rnc Capital Management’s portfolio.

On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Leave a Reply

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.